Watch ERNA. Know when insiders buy.
One email the day a filing lands. Free.
ERNA
Ernexa Therapeutics Inc.
4.17
+0.15 +3.73%
USD · close Sep 11
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6.8MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$12.3MNET CASH $3.6M52W 3.28 – 47.00SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$4.1M | −$4M | — | -3.40 | −$4.2M | $3K | −$4.2M | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$5.6M | −$5.5M | — | -6.95 | −$2.3M | $2K | −$2.3M | May 11 |
| Q4 2025 · Dec 31derived | — | — | — | −$2.1M | −$1.5M | — | -0.01 | −$1.1M | $15K | −$1.2M | Mar 13 |
| Q3 2025 · Sep 30 | — | — | — | −$2M | −$1.2M | — | -0.15 | −$1.3M | — | — | Nov 7 |
| Q2 2025 · Jun 30 | — | — | — | −$2.5M | −$3.1M | — | -15.19 | −$2.5M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$2.7M | −$8.2M | — | -57.76 | −$2.1M | — | — | May 11 |
| Q4 2024 · Dec 31derived | $1K | −94.1% | 100.0% | −$2.7M | −$5.8M | — | 58.49 | −$3.5M | $0 | −$3.5M | Mar 13 |
| Q3 2024 · Sep 30 | $487K | +854.9% | 112.3% | −$2.3M | −$26.6M | — | -73.70 | −$6.3M | $19K | −$6.3M | Nov 7 |
| Q2 2024 · Jun 30 | $47K | — | -102.1% | −$4.9M | −$5.5M | — | -15.34 | −$2.3M | $249K | −$2.5M | Aug 13 |
| Q1 2024 · Mar 31 | $47K | — | -29.8% | −$5.8M | −$6.6M | — | -1.23 | −$3.7M | $101K | −$3.8M | May 7 |
| Q4 2023 · Dec 31derived | $17K | — | -288.2% | −$5.8M | −$6.2M | — | -1.14 | −$4.7M | $19K | −$4.7M | Mar 12 |
| Q3 2023 · Sep 30 | $51K | — | -135.3% | −$5.5M | −$5.6M | — | -1.03 | −$5.8M | $0 | −$5.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$9.3M | −$14.1M | — | -2.24 | −$7M | $37K | −$7.1M | — | — |
| FY2024 · to Dec 31 | $582K | 83.5% | −$15.7M | −$44.5M | -7652.7% | -48.96 | −$15.8M | $369K | −$16.2M | — | — |
| FY2023 · to Dec 31 | $68K | -247.1% | −$21.1M | −$21.7M | -31864.7% | -4.08 | −$20.4M | $19K | −$20.4M | — | — |
| FY2022 · to Dec 31 | $0 | — | −$33.2M | −$24.6M | — | -8.06 | −$21M | $297K | −$21.3M | — | — |
| FY2021 · to Dec 31 | — | — | −$113.7M | −$122.5M | — | -56.61 | −$23.5M | $154K | −$23.6M | — | — |
| FY2020 · to Dec 31 | $5.8M | — | −$7.2M | −$7.3M | -125.7% | -0.41 | −$8.1M | $39K | −$8.1M | — | — |
Every number comes from Ernexa Therapeutics Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.